Lynparza
(Fluzoparib)Phase 3Small molecule
Fluzoparib is used to treat certain cancers, particularly those with specific genetic mutations like BRCA mutations, by blocking a protein that helps cancer cells repair their DNA.[1] Lynparza is currently being investigated across 19 indications[3], with its most advanced program in Phase 3.[1]
Lynparza is one of 544 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
19
Indications
55
Total Trials
22
Active Trials
543
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Cancer14 trials
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
Unknown status·TThe Second Affiliated Hospital of Shandong First Medical University·Phase 2·NCT05170594·60 enrolled
Show 11 more trials
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Not yet recruiting·—·Phase 3·NCT06539091·51 enrolled
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 3·NCT06188455·37 enrolled
Breast Cancer12 trials
Show 9 more trials
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled
Pancreatic Cancer3 trials
Small Cell Lung Cancer3 trials
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Not yet recruiting·—·Phase 1/2·NCT07141771·100 enrolled
19 more indications
Function2 trials
Preoperative1 trial
Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)
Completed·—·Phase 2·NCT05938374·52 enrolled
Endometrial Cancer1 trial
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Recruiting·—·Phase 2·NCT06413992·117 enrolled
Ovarian Carcinoma1 trial
Neoadjuvant Therapy1 trial
Non-Small Cell Lung Cancer1 trial
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04828395·65 enrolled
Gastric Cancer1 trial
Renal Cell Carcinoma1 trial
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04535687·1 enrolled
Soft Tissue Sarcoma1 trial
Recurrent Ovarian Cancer1 trial
Advanced Solid Malignancies1 trial
Metastatic Colorectal Cancer1 trial
Patients With Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluzoparib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details